基于脂质体和纳米材料的针对性阿尔茨海默病治疗策略
Balajothi Balagurusamy1, Vinodha Ganesan2, Vidya Gopi3
1Department of Chemistry, AMC Engineering College, Bangalore 560083, India.
ACS omega
|December 22, 2025
概括
脂质体为阿尔茨海默病 (AD) 治疗提供了一种有前途的方法,通过增强跨血脑屏障的药物输送. 这些先进的纳米载体提高了药物的稳定性和向性,显示了神经保护和减少粉样β斑块的潜力.
科学领域:
- 神经科学和药理学 神经科学和药理学
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,有效治疗方法有限.
- 目前的治疗策略面临的挑战是药物的生物可用性和穿越血脑屏障.
- 脂质体药物输送为AD中增强的向药物输送提供了一个可行的解决方案.
研究的目的:
- 审查脂质体和纳米材料在阿尔茨海默氏症治疗中的应用.
- 探索各种脂肪体配方及其治疗潜力.
- 突出抑制粉样β聚合和增强大脑向的策略.
主要方法:
- 对阿尔茨海默病的脂质体配方现有文献的审查.
- 对不同脂质体修饰的分析 (例如,曼诺糖修饰,抗体向).
- 研究天然化合物载体及其神经保护作用.
- 探索针对粉样β聚合和促进清除的策略.
主要成果:
- 脂质体表现出用于鼻内输送,基因疗法和ROS响应系统的多功能性.
- 修改后的脂质体 (曼诺斯,抗体,外体类) 显示出改善的治疗疗效.
- 脂质体中的天然化合物提供神经保护.
- 向性脂质体有效地抑制了粉样β聚合.
- 淋巴清除和微质细胞化通过脂质体策略得到增强.
结论:
- 脂质体药物递送系统为推进阿尔茨海默病治疗提供了显著的潜力.
- 这些系统提高了药物的稳定性,特异性和脑向效率.
- 脂质体代表了一个有前途的平台,用于开发新的神经保护和抗粉样蛋白治疗阿尔茨海默病.
更多相关视频
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
1.1K
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
3.0K
相关概念视频
Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
siRNA - Small Interfering RNAs
18.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.3K
